Brian Goodman
29Patents
7h-index
64Co-inventors
68Inventor score
Filing activity: Feb 4, 2014 → Feb 28, 2025
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9011834B1 | Compositions and methods | Emerging Cross-Sectional Technologies | 234 | Active |
| US9180147B2 | Compositions and methods | Emerging Cross-Sectional Technologies | 88 | Active |
| US9446080B2 | Compositions and methods | Emerging Cross-Sectional Technologies | 79 | Active |
| US9585921B2 | Compositions and methods | Emerging Cross-Sectional Technologies | 44 | Active |
| US9855303B2 | Compositions and methods | Emerging Cross-Sectional Technologies | 25 | Active |
| US10064900B2 | Methods of populating a gastrointestinal tract | Emerging Cross-Sectional Technologies | 19 | Active |
| US10064901B2 | Compositions and methods | Emerging Cross-Sectional Technologies | 18 | Active |
| US10967011B2 | Compositions and methods | Emerging Cross-Sectional Technologies | 7 | Active |
| US9956282B2 | Bacterial compositions and methods of use thereof for treatment of immune system disorders | Emerging Cross-Sectional Technologies | 7 | Active |
| US10493113B2 | Compositions and methods for treating disease using a Blautia strain | Emerging Cross-Sectional Technologies | 6 | Active |
| US11603396B2 | Circular RNA compositions and methods | Emerging Cross-Sectional Technologies | 5 | Active |
| US10702561B2 | Pharmaceutical compositions comprising a Blautia strain | Emerging Cross-Sectional Technologies | 4 | Active |
| US11679120B2 | Circular RNA compositions and methods | Emerging Cross-Sectional Technologies | 4 | Active |
| US11524037B2 | Bacterial extracellular vesicles | Emerging Cross-Sectional Technologies | 1 | Active |
| US11802144B2 | Circular RNA compositions and methods | Emerging Cross-Sectional Technologies | 1 | Active |
| US10576111B2 | Method of treating cancer using Bifidobacterium animalis ssp. lactis strain PTA-125097 | Human Necessities | 1 | Active |
| US11730775B2 | Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof | Emerging Cross-Sectional Technologies | 1 | Active |
| US12054739B2 | Engineered retrons and methods of use | Chemistry; Metallurgy | 0 | Active |
| US10792314B2 | Compositions and methods of treating cancer using Bifidobacterium animalis ssp. lactis | Human Necessities | 0 | Active |
| US11766481B2 | Glycan modified short interfering RNA | Human Necessities | 0 | Active |
| US11266700B2 | Compositions and methods for treating immune disorders using immune modulating Lactococcus bacteria strains | Emerging Cross-Sectional Technologies | 0 | Active |
| US12109243B2 | Bacterial extracellular vesicles | Emerging Cross-Sectional Technologies | 0 | Active |
| US11090341B2 | Compositions and methods for treating cancer and immune disorders using Veillonella bacteria | Emerging Cross-Sectional Technologies | 0 | Active |
| US12427212B2 | Nectin-4 binding miniproteins, conjugates and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US11771715B2 | Circular RNA compositions and methods | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.